About
CereGate is a German neurotechnology company founded in 2019 and based in Hamburg. The company specializes in developing a Computer-Brain Interface (CBI) platform that facilitates direct communication with the human brain. Their technology is compatible with existing neuromodulation implants, such as Deep Brain Stimulation (DBS) and Spinal Cord Stimulation (SCS) devices, and is designed to enhance the treatment of neurological and psychiatric disorders. Currently, CereGate focuses on improving gait and balance symptoms in Parkinson’s disease patients and addressing vestibular disorders. CereGate’s software platform utilizes advanced neuromodulation technology to modulate neural activity, aiming to restore human senses and improve patients' quality of life. The company has conducted over 85 successful patient trials, demonstrating the effectiveness of their solutions. They are pursuing FDA trials and Breakthrough Device status, highlighting their commitment to innovation. CereGate's technology is adaptable and scalable, making it suitable for various medical conditions and appealing for partnerships in the medtech industry.
Technologies
Keywords
Company Information
-
Employees 13
-
Founded 2019
Location
Munich, Bavaria, Germany, 80539